Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

779
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
779
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.0K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

383
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
383
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

858
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
858
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

1.0K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.0K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality measures in the design, conduct, and reporting of endoscopic research.

Gastrointestinal endoscopy·2026
Same author

International Consensus Statements on the Use of Topical Endoscopic Hemostatic Powders in the Treatment of Acute Gastrointestinal Bleeding.

Journal of clinical gastroenterology·2026
Same author

Endosonography-guided choledochoduodenostomy using a lumen apposing metal stent vs. ERCP: Individual patient data and aggregate meta-analyses.

Endoscopy international open·2026
Same author

Implementation of a prospective video databank for artificial intelligence model development, validation and clinical outcomes research in gastrointestinal endoscopy.

Gastrointestinal endoscopy·2026
Same author

Impact of care reorganisation during COVID-19 waves on non-COVID-19 inpatients in a Swiss hospital: a retrospective cohort study.

Swiss medical weekly·2026
Same author

A National Prospective Multicenter Comparison of Risk Scores Against Clinical Judgement for the Prediction of Safe Discharge From the Emergency Department in Patients Presenting With Lower Gastrointestinal Bleeding.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Related Experiment Video

Updated: Jan 2, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.3K

Proton pump inhibitors for upper gastrointestinal bleeding.

Omar Kherad1, Sophie Restellini2, Myriam Martel3

  • 1Internal Medicine Department, La Tour Hospital and University of Geneva, Switzerland.

Best Practice & Research. Clinical Gastroenterology
|December 2, 2019
PubMed
Summary

Proton pump inhibitors (PPIs) are crucial for managing acute upper gastrointestinal bleeding (UGIB). This review examines optimal PPI timing, dosage, and administration for improved patient outcomes in UGIB management.

Keywords:
EndoscopyHemorrhageProton pump inhibitorUpper gastrointestinal bleeding

More Related Videos

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
05:50

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care

Published on: September 22, 2023

4.1K
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

1.2K

Related Experiment Videos

Last Updated: Jan 2, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.3K
Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
05:50

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care

Published on: September 22, 2023

4.1K
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

1.2K

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Clinical Pharmacology

Background:

  • Acute upper gastrointestinal bleeding (UGIB) presents a significant public health challenge with high mortality rates.
  • Proton pump inhibitors (PPIs) are frequently used alongside endoscopic procedures for UGIB, but optimal therapeutic strategies remain debated.
  • Current management guidelines lack definitive recommendations on PPI administration timing, dosage, and delivery methods in acute UGIB.

Purpose of the Study:

  • To critically evaluate the existing evidence regarding the use of proton pump inhibitors in the acute management of upper gastrointestinal bleeding.
  • To analyze the impact of PPI timing, dosage, and administration route on clinical outcomes in UGIB patients.
  • To provide evidence-based insights into optimizing PPI therapy in the peri-endoscopic and short-term post-discharge phases of UGIB care.

Main Methods:

  • Systematic review of current scientific literature and clinical trial data on PPI use in acute UGIB.
  • Analysis of evidence concerning pre-endoscopic, peri-endoscopic, and post-discharge PPI administration strategies.
  • Evaluation of studies investigating various PPI dosages and modes of administration (e.g., intravenous vs. oral).

Main Results:

  • Evidence suggests that high-dose intravenous PPI therapy prior to endoscopy may be beneficial in selected high-risk UGIB patients.
  • The optimal timing and duration of PPI therapy post-endoscopy require further investigation, with current practices varying widely.
  • Comparative studies on different PPI dosages and administration routes show mixed results, highlighting the need for personalized treatment approaches.

Conclusions:

  • Proton pump inhibitors play a vital role in managing acute upper gastrointestinal bleeding, but optimal therapeutic regimens are still under investigation.
  • Further research is warranted to establish definitive guidelines for PPI timing, dosage, and administration to improve patient outcomes and reduce mortality in UGIB.
  • Personalized PPI strategies, considering patient risk factors and endoscopic findings, are essential for effective acute UGIB management.